Quick Answer
Orchestra BioMed Holdings, Inc. reported Total Revenue of $33.48 million for fiscal year 2025.
Orchestra BioMed Holdings, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $33.48M +1169.2% |
$2.64M -4.4% |
$2.76M -21.9% |
$3.53M | — | — |
| Net Income | -$52.70M +13.6% |
-$61.02M -24.2% |
-$49.12M -46.2% |
-$33.61M -8773.3% |
-$378.8K | — |
| Diluted EPS | -$1.11 +33.1% |
-$1.66 -12.2% |
-$1.48 +33.9% |
-$2.24 -11100.0% |
-$0.02 | — |
| Total Assets | $114.86M +50.8% |
$76.17M -20.0% |
$95.21M -0.4% |
$95.57M -40.9% |
$161.82M -0.2% |
$162.16M |
| Cash and Equivalents | $34.69M +55.8% |
$22.26M -27.2% |
$30.56M +54.5% |
$19.78M +1027.6% |
$1.75M -13.4% |
$2.03M |
| Stockholders Equity | $53.57M +62.5% |
$32.96M -51.6% |
$68.04M +1079.8% |
-$6.94M -76.2% |
-$3.94M -10.6% |
-$3.56M |
| R&D Expense | $58.19M +35.9% |
$42.80M +26.6% |
$33.82M +54.1% |
$21.95M | — | — |
| Operating Income | -$51.81M +19.4% |
-$64.30M -24.8% |
-$51.51M -57.7% |
-$32.66M -8172.7% |
-$394.8K | — |
| Shares Outstanding | 57.03M +49.3% |
38.19M +6.8% |
35.78M +77.2% |
20.19M +353.7% |
4.45M +0.0% |
4.45M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $861.0K | -12.8% | +3.0% |
| Net Income | September 30, 2025 | -$20.83M | -35.0% | -7.6% |
| Diluted EPS | September 30, 2025 | -$0.40 | +2.4% | +20.0% |
| Total Assets | September 30, 2025 | $104.81M | +39.2% | +144.7% |
| Cash and Equivalents | September 30, 2025 | $42.01M | +64.1% | +124.1% |
| Stockholders Equity | September 30, 2025 | $43.74M | -5.4% | +14726.8% |
| R&D Expense | September 30, 2025 | $14.03M | +21.0% | +1.3% |
| Operating Income | September 30, 2025 | -$20.31M | -24.3% | -5.1% |
| Shares Outstanding | September 30, 2025 | 56.46M | +48.8% | +46.1% |
- Orchestra BioMed Holdings, Inc. reported Total Revenue of $33.48 million for fiscal year 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +1169.2% in Total Revenue compared to the prior fiscal year.
- Orchestra BioMed Holdings, Inc. reported Net Income of -$52.70 million for fiscal year 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +13.6% in Net Income compared to the prior fiscal year.
- Orchestra BioMed Holdings, Inc. reported Diluted EPS of $1.11 per share (loss) for fiscal year 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +33.1% in Diluted EPS compared to the prior fiscal year.
- Orchestra BioMed Holdings, Inc. reported Total Assets of $114.86 million for fiscal year 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +50.8% in Total Assets compared to the prior fiscal year.
- Orchestra BioMed Holdings, Inc. reported Cash and Equivalents of $34.69 million for fiscal year 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +55.8% in Cash and Equivalents compared to the prior fiscal year.
- Orchestra BioMed Holdings, Inc. reported Stockholders Equity of $53.57 million for fiscal year 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +62.5% in Stockholders Equity compared to the prior fiscal year.
- Orchestra BioMed Holdings, Inc. reported R&D Expense of $58.19 million for fiscal year 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +35.9% in R&D Expense compared to the prior fiscal year.
- Orchestra BioMed Holdings, Inc. reported Operating Income of -$51.81 million for fiscal year 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +19.4% in Operating Income compared to the prior fiscal year.
- Orchestra BioMed Holdings, Inc. reported Shares Outstanding of 57.03 million shares for fiscal year 2025.
- Orchestra BioMed Holdings, Inc. showed an increase of +49.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: